Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man
- Sponsors BioCryst Pharmaceuticals
- 05 Nov 2018 According to BioCryst media release, the data will be presented at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2018.
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 08 Feb 2016 Results from this trial are expected by the end of 2016, according to a BioCryst media release.